KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. PMID 39448200 · J Immunother Cancer · 2024-Oct-23 The record describes a secondary analysis of a Phase II randomized trial. While it is an original result report with a time-to-event endpoint and drug intervention, the trial phase (Phase II) does not meet the definitive Phase III/IIIb or Phase II/III criterion. Furthermore, the primary focus of this report is a subgroup analysis based on genomic alterations, not the primary efficacy report of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. PMID 39438442 · Signal Transduct Target Ther · 2024-Oct-23 This record is a biomarker analysis article that references and uses data from the phase 3 CONTINUUM, DIPPER, and OAK trials, but it does not present itself as the primary efficacy report of any of these trials. Its focus is on identifying predictive biomarkers (Ki67+ Tregs) for immunotherapy benefit. While it mentions trials, phases, and endpoints, the article itself is not an original formal-result report of a randomized trial's efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Feasibility, acceptability, and preliminary efficacy of a self-directed online psychosocial intervention for women with metastatic breast cancer: Finding My Way-Advanced. PMID 39438337 · Support Care Cancer · 2024-Oct-22 The record is a randomized, human, oncology study reporting original results, but it is a feasibility/pilot study (not Phase III/IIIb or Phase II/III), evaluates a non-drug psychosocial intervention, and does not report a time-to-event efficacy endpoint (it reports distress, QOL, and unmet needs as outcomes).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A study of intersphincteric resection rate following robotic-assisted total mesorectal excision versus laparoscopic-assisted total mesorectal excision for patients with middle and low rectal cancer: study protocol for a multicenter randomized clinical trial. PMID 39434171 · Trials · 2024-Oct-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. PMID 38955475 · Ann Rheum Dis · 2024-Oct-21 Study is a randomized Phase III trial with drug intervention (olokizumab + methotrexate) in humans, but the disease is rheumatoid arthritis (RA), not human malignant neoplasm (oncology). It is excluded based on non-oncology condition.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials. PMID 39173088 · J Clin Oncol · 2024-Oct-20 The study is a randomized, placebo-controlled trial of menopausal hormone therapy (drug intervention) with time-to-event oncology endpoints (incidence and mortality of ovarian and endometrial cancers, reported with hazard ratios). However, the abstract and metadata do not explicitly establish the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion. The deterministic review signal also indicates phase3 evidence is unclear. Therefore, it cannot be confirmed as eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. PMID 39047219 · J Clin Oncol · 2024-Oct-20 The record describes a secondary biomarker analysis of a randomized trial, which is excluded as it is not the primary formal-result report of the trial's overall efficacy. The trial phase (Phase III/IIIb) is not explicitly stated in the provided metadata, leading to a null confidence for that criterion, but the primary exclusion is based on report type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial. PMID 39028918 · J Clin Oncol · 2024-Oct-20 While the record describes a human randomized trial with a drug intervention and reports a time-to-event endpoint (colorectal cancer death HR), the primary endpoint of the trial (colorectal cancer incidence) is not the key efficacy endpoint for the drug's intended use. The report is a secondary analysis/update on a specific outcome from a large, multifactorial preventive trial (WHI), not a definitive oncology Phase III trial for a therapeutic drug. The trial phase is also not confirmed as Phase III in the metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Expression of CD4+T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis. PMID 38797702 · Tohoku J Exp Med · 2024-Oct-19 The record describes a randomized trial of ruxolitinib in myeloproliferative neoplasms with time-to-event data, but the explicit Phase III/IIIb or Phase II/III designation is missing from the provided metadata and abstract. Therefore, the 'phase3_or_definitive' criterion is not established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The TELEhealth Shared decision-making COaching and navigation in Primary carE (TELESCOPE) intervention: a study protocol for delivering shared decision-making for lung cancer screening by patient navigators. PMID 39425032 · BMC Prim Care · 2024-Oct-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Suprathel Versus Hypafix in the Management of Split-Thickness Donor Site Wounds in the Elderly: A Randomised Controlled Trial. PMID 39727907 · Eur Burn J · 2024-Oct-17 The study is a randomized trial in oncology patients but lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint as defined by the criteria. The primary outcome is 'time to healing,' which is a continuous measure of wound healing, not a formal survival or progression endpoint analyzed with Kaplan-Meier curves or hazard ratios for malignant neoplasm outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial). PMID 39415282 · Trials · 2024-Oct-17 This is a protocol for an ongoing randomized trial in bladder cancer (oncology) using a drug-containing intervention (immunonutrition). It is not a completed trial report with results, and the specified time-to-event efficacy endpoints are not the primary focus. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Study protocol for a multicentre randomised controlled trial evaluating the efficacy of an online yoga intervention in high-grade glioma patients and their caregivers: the YINOTA-O-trial. PMID 39414288 · BMJ Open · 2024-Oct-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of a mobile health intervention based on a multitheoretical model of health behavior change on anxiety and depression, fear of cancer progression, and quality of life in patients with differentiated thyroid cancer: A randomized controlled trial. PMID 39407174 · BMC Med · 2024-Oct-15 The trial is a randomized oncology study in humans with primary results, but it evaluates a non-drug mHealth intervention and does not include a time-to-event endpoint like OS, PFS, etc.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeted axillary dissection using carbon marking for patients with node-positive breast cancer following neoadjuvant therapy (TADCOM): study protocol for a prospective, multicenter, randomized controlled trial. PMID 39402559 · BMC Cancer · 2024-Oct-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. PMID 39106081 · Clin Cancer Res · 2024-Oct-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer. PMID 38986608 · Med · 2024-Oct-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. PMID 39383458 · N Engl J Med · 2024-Oct-10 The record is an original result report from a Phase 2-3 study of a drug-containing intervention (gene therapy) in a human oncology context. However, it is not randomized (randomized: false) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The study's focus is on safety (hematologic cancer incidence) and integration-site analysis, not on a Kaplan-Meier or HR-based efficacy endpoint. Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial. PMID 39083705 · J Clin Oncol · 2024-Oct-10 The report is a secondary biomarker analysis within the QUASAR trial, focusing on the prognostic and predictive value of T-cell immunohistochemistry for recurrence-free interval, not the trial's primary or key secondary time-to-event efficacy endpoint (e.g., OS or DFS for the drug comparison). While it involves a randomized trial with a drug intervention, it does not constitute the original definitive efficacy report required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Interventions for BK virus infection in kidney transplant recipients. PMID 39382091 · Cochrane Database Syst Rev · 2024-Oct-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study. PMID 39375801 · Trials · 2024-Oct-08 The record is a methodological/secondary analysis of multiple clinical trials, not an original result report of a single randomized trial. It lacks a time-to-event efficacy endpoint and does not report on a drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109). PMID 39375745 · Breast Cancer Res · 2024-Oct-07 The record describes a primary analysis of a Phase III randomized trial with a drug intervention and time-to-event efficacy endpoints. Randomization is explicitly stated in the study design ('PALLAS is an open, international, phase 3 study...'). The analysis is of the original intention-to-treat population, not a post-hoc subgroup, and includes key efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
Prospective observational non-randomized trial protocol for surgical planner 3D image processing & reconstruction for locally advanced colon cancer. PMID 39375653 · BMC Surg · 2024-Oct-07 This is a non-randomized, non-drug, surgical/imaging protocol for colon cancer. It is not a randomized drug trial and does not contain results for a Phase III/IIIb or Phase II/III trial with a drug intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial. PMID 38964854 · Gut · 2024-Oct-07 The record describes a randomized trial comparing two endoscopic mucosal resection techniques (cold vs hot snare) for colorectal polyps, which is an oncology-related procedure. However, it lacks a drug-containing intervention (both arms are procedural) and lacks a time-to-event primary endpoint (primary outcome is recurrence at a fixed time point, reported as proportion, not time-to-event such as OS/PFS with Kaplan-Meier analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Evaluation of the 10-year protective effect and immunogenicity of quadrivalent HPV vaccination]. PMID 39428235 · Zhonghua Yu Fang Yi Xue Za Zhi · 2024-Oct-06 The report is an original result from a Phase III randomized trial of a quadrivalent HPV vaccine (drug intervention) in humans with a focus on cervical neoplasia (oncology). However, the study's primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The endpoints are descriptive (abnormal cervical cytology proportion, CIN case counts, antibody titers, and positive rates). The study is a long-term follow-up analysis, but it does not report time-to-event efficacy data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-world study on the application of enhanced recovery after surgery protocol in video-assisted thoracoscopic day surgery for pulmonary nodule resection. PMID 39367357 · BMC Surg · 2024-Oct-05 The study is a randomized controlled trial in oncology (Lung Neoplasms) reporting postoperative recovery outcomes, but it is not a Phase III/IIIb or definitive Phase II/III trial, does not involve a drug-containing intervention, and does not have a time-to-event efficacy endpoint like OS or PFS. The endpoints are postoperative recovery indicators (e.g., chest tube duration, mobilization time) and complications, not survival or progression.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. PMID 39589370 · N Engl J Med · 2024-Oct-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults. PMID 39189761 · Microbiol Spectr · 2024-Oct-03 The study is a randomized trial in a healthy adult population investigating the effects of vitamin D3 supplementation on the gut microbiome and metabolites, with a stated relevance to colorectal cancer prevention. However, it does not meet the key criteria for the cohort: it is not explicitly a Phase III or definitive trial, the intervention is a dietary supplement (not a drug), and the endpoints are mechanistic (microbiota composition, metabolites) rather than clinical time-to-event outcomes like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. PMID 38990195 · Oncologist · 2024-Oct-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial. PMID 38558247 · Oncologist · 2024-Oct-03 Eligibility requires a drug-containing intervention. This trial evaluates early palliative care (a non-drug supportive care intervention) versus standard oncological care. While it meets other criteria (oncology, human, randomized, Phase III-level definitive evidence unclear, time-to-event endpoint, original result), the absence of a specified drug-containing intervention arm excludes it.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538. PMID 39446327 · JAMA Netw Open · 2024-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial. PMID 39431961 · Crit Care Explor · 2024-Oct-01 The study is a randomized controlled trial in cancer patients, but the intervention is procalcitonin-guided antibiotic management, not a drug therapy. The primary endpoint is time to antibiotic cessation, which is not an oncology efficacy time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves or hazard ratios for oncology outcomes are reported. Therefore, it does not meet the inclusion criteria for a drug intervention trial with a key oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. PMID 39356138 · Cancer Res Commun · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. PMID 39158894 · JAMA · 2024-Oct-01 The study is a Phase III randomized trial in an oncologic setting (liver resection for cancer), but it lacks a time-to-event efficacy endpoint (primary outcome is transfusion receipt). The intervention is tranexamic acid, an antifibrinolytic agent used to reduce bleeding, not a systemic anticancer drug. Therefore, it does not meet the criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. PMID 39145953 · JAMA Oncol · 2024-Oct-01 The record is a prospective-retrospective translational study (biomarker analysis) of the SOFT trial. While it involves a randomized trial with drug interventions and time-to-event endpoints, the trial phase (III/IIIb) is not explicitly confirmed in the provided text or metadata. The deterministic review signal indicates 'phase3_evidence_unclear'. Therefore, the criterion 'phase3_or_definitive' cannot be established, making eligibility uncertain. The report_type is 'other' as it is a translational/subgroup analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial. PMID 39115975 · JAMA Oncol · 2024-Oct-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). PMID 39115414 · Clin Cancer Res · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. PMID 39092963 · J Antimicrob Chemother · 2024-Oct-01 The study is a randomized, original clinical trial in oncology patients evaluating a drug-containing intervention. However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). The primary outcome is clinical response at end-of-IV therapy, which is a categorical (favorable/unfavorable) endpoint, not a time-to-event endpoint. Therefore, it does not meet the required inclusion criteria for time-to-event efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia. PMID 39078289 · Clin Cancer Res · 2024-Oct-01 This is a pharmacogenomic subgroup analysis of two underlying randomized trials (AML02 and AML08). The title and abstract do not explicitly state the phase of the underlying trials (they are not labeled as Phase III). The analysis focuses on tailoring treatment based on a biomarker score, which constitutes a subgroup analysis. Therefore, it is excluded as it is not a primary report of a definitive-phase randomized trial with a drug intervention and primary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD). PMID 39069901 · Ann Surg · 2024-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients? PMID 39017207 · Anticancer Drugs · 2024-Oct-01 The study is a randomized trial in oncology patients but does not have a primary/key secondary time-to-event efficacy endpoint. It focuses on a safety/toxicity prevention outcome (nephrotoxicity) with biomarker endpoints, not the required efficacy survival endpoints (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY-PLENTY pilot study. PMID 38995162 · Int J Surg · 2024-Oct-01 The record describes a pilot randomized study, not a Phase III or Phase II/III trial as required by the cohort criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Accuracy of Medical Oncology Prognosis for Metastatic Cancer Patients Evaluated for Enrollment Onto an Ongoing Randomized Clinical Trial. PMID 38992872 · Am J Clin Oncol · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patients with stage IV colorectal carcinoma selected for palliative primary tumor resection and systemic therapy survive longer compared with systemic therapy alone: a retrospective comparative cohort study. PMID 38935125 · Int J Surg · 2024-Oct-01 The study is a retrospective comparative cohort study, not a randomized controlled trial or a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. PMID 38898626 · Int J Cancer · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. PMID 38695123 · Haematologica · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer. PMID 38583494 · Int J Radiat Oncol Biol Phys · 2024-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidence, predictors, and outcomes of malignant cerebral edema in acute basilar artery occlusion after endovascular treatment: a secondary analysis of the ATTENTION trial. PMID 38579342 · J Neurosurg · 2024-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Green Tea Consumption on Postoperative Ileus in Colon Cancer Patients: A Pilot Randomized Controlled Trial. PMID 39583370 · Cureus · 2024-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Axillary Lymph Node Dissection versus Loco-regional Radiotherapy in Management of the Axilla in Node-Negative Locally Advanced Breast Cancer Post Neoadjuvant Chemotherapy. PMID 39520209 · Chirurgia (Bucur) · 2024-Oct The study is a randomized trial in oncology comparing surgical versus radiotherapy management, but it is not Phase III/IIIb or Phase II/III (phase not specified), lacks a drug-containing intervention (interventions are surgical and radiotherapy), and does not report a time-to-event efficacy endpoint (only reports on lymphedema rates and loco-regional recurrence as categorical outcomes without Kaplan-Meier or HR data).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -